Pearson
FDA request for reconsideration of court order requiring disclaimers for folic acid/NTD supplement health claim is baseless and demonstrates agency's "reluctance to fully comply with Pearson I," D.C. federal court Judge Gladys Kessler says in May 7 order upholding her prior ruling. Agency had argued Kessler committed "clear error" by "assigning undue weight" to 1992 human clinical study conducted in Hungary and creating legal standard inconsistent with D.C. appeals court's original decision requiring FDA to consider disclaimers for four Pearson claims. In April, FDA released disclaimer language for .8 mg folic acid/NTD reduction health claim (1"The Tan Sheet" April 9, In Brief)
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
With a 25-27 June meeting looming, HHS Secretary Robert F. Kennedy Jr. can fill all 17 spots on the CDC's Advisory Committee on Immunization Practices with people he says will "exercise independent judgment."
The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.
Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.